Jazz Pharmaceuticals’ CEO Bruce Cozadd joins Acelyrin’s board

The clinical-stage biopharma Acelyrin has appointed Bruce C. Cozadd, co-founder and CEO of Jazz Pharmaceuticals (Nasdaq:JAZZ), to its board of directors.

Cozadd co-founded Jazz Pharmaceuticals in 2003. Last year, the company brought in $3 billion in revenue. Cozadd continues to serve as the company’s chairperson and CEO.

Bruce Cozadd

Before taking the helm of Jazz Pharmaceuticals, Cozadd served as the chief operating officer of Alza Corp., which merged with Johnson & Johnson in 2001.

He is currently a member of the board of the Biotechnology Innovation Organization (BIO) and also serves on the boards of two non-profits.

“His success as a biopharma leader has given hope to patients around the world, and his perspectives will help Acelyrin build our capabilities, drive growth for our investors, and realize our vision of accelerating the development of life-changing medicines to help pa…

Read more
  • 0

FDA approves Jazz Pharmaceuticals’ for idiopathic hypersomnia 

Jazz Pharmaceuticals (NSDQ:JAZZ) has announced that its Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution has won FDA approval for treating idiopathic hypersomnia in adults.

Idiopathic hypersomnia is a rare chronic disorder involving chronic excessive daytime sleepiness.

Previously, the drug was FDA approved for treating cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.

FDA first approved a related drug, sodium oxybate, for narcolepsy in 2002. At that point, Orphan Medical was its manufacturer. Jazz Pharmaceuticals acquired that company in 2005.

As the drug is a central nervous system depressant, Jazz plans to make the drug available to patients with idiopathic hypersomnia later in 2021 after performing a Risk Evaluation and Mitigation Strategies (REMS) implementation.

In 2007, Jazz paid a $20 million fine for off-label marketing of the related drug, Xyrem (sodium…

Read more
  • 0